文献速递白血病

硼替佐米联合利妥昔单抗治疗新诊断青少年/成人CD20阳性Ph阴性前B细胞急性淋巴细胞白血病

Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2021-01-01

该2期研究评估硼替佐米联合利妥昔单抗及儿科启发方案诱导治疗新诊断CD20阳性Ph阴性前B-ALL(年龄>14岁)的活性。35例患者中,诱导结束骨髓MRD阴性率达70.9%,高于历史单纯化疗队列的51.7%,巩固后升至87.5%。中位随访21个月,EFS和OS分别为78.8%和78.7%,神经病变发生率26%(均<3级)。

要点

  • 诱导结束MRD阴性率70.9%,历史对照51.7%
  • 巩固后MRD阴性率升至87.5%
  • 神经病变发生率26%,均<3级

核心结论

  • 硼替佐米、利妥昔单抗联合儿科启发方案在新诊断CD20阳性Ph阴性前B-ALL中具有活性且耐受良好。

研究设计与样本

  • 2期研究,纳入新诊断青少年和成人(年龄>14岁)CD20阳性Ph阴性前B-ALL患者35例。

主要发现

  • 诱导结束MRD阴性率为70.9%,历史单纯化疗队列为51.7%。
  • 巩固后MRD阴性率提高至87.5%。
  • 中位随访21个月,无事件生存率78.8%(95%CI 66-94),总生存率78.7%(95%CI 65.8-94)。
  • 与历史队列相比,硼替佐米和利妥昔单抗未显著增加毒性,神经病变发生率26%(均<3级)。

关键数值与推荐

  • 主要终点为诱导结束骨髓MRD阴性。

临床怎么用

  • 该联合方案可用于新诊断CD20阳性Ph阴性前B-ALL的诱导治疗,以提高MRD阴性率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The expression of CD20 in precursor B-cell acute lymphoblastic leukemia (B-ALL) is associated with poor outcomes. The addition of rituximab to intensive chemotherapy in CD20+ ALL has led to improved outcomes in several studies. However, there is no clear evidence regarding the optimal number of doses and its benefit without an allogeneic stem cell transplant. Achieving measurable residual disease (MRD)-negative status postinduction would reduce the requirement for a transplant. Novel approaches are needed to induce a higher proportion of MRD-negative complete remission in patients with high-risk ALL. Given bortezomib's activity in relapsed ALL and its synergism with rituximab in B-cell lymphomas, the addition of bortezomib to rituximab and chemotherapy may provide an incremental benefit in CD20+ precursor B-ALL. We conducted a phase 2 study to test the activity of bortezomib and rituximab in combination with a pediatric-inspired regimen during induction therapy in newly diagnosed adolescents and adults (aged >14 years) with CD20+, Philadelphia-negative precursor B-ALL; bone marrow MRD negativity at the end of induction was the primary end point. From December 2017 through August 2019, a total of 35 patients were enrolled. End-of-induction MRD-negative status was achieved in 70.9% of patients, as opposed to 51.7% in the historical cohort treated with chemotherapy alone. MRD-negative rates improved to 87.5% post-consolidation. At a median follow-up of 21 months, event-free survival and overall survival rates were 78.8% (95% confidence interval, 66-94) and 78.7% (95% confidence interval, 65.8-94), respectively. There was no significant increase in toxicity with bortezomib and rituximab compared with the historical cohort. The incidence of neuropathy was 26% (all less than grade 3). The combination of bortezomib, rituximab, and a pediatric-inspired ALL regimen was active and well tolerated in de novo CD20+ Philadelphia-negative precursor B-ALL. This trial was registered with the Clinical Trials Registry-India as CTRI/2017/04/008393(http://ctri.nic.in/Clinicaltrials).

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Jain H, Sengar M, Goli VB, et al. Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia. Blood Adv. 2021. PMID: 34461632. doi:10.1182/bloodadvances.2020003368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。